WilmerHale Counsels Decibel Therapeutics in $55M Series C Financing

  • 6.20.2018

Decibel Therapeutics, Inc., a company dedicated to the discovery and development of breakthrough medicines to treat hearing loss and hearing-related disorders, announced on June 19, 2018, the closing of a $55 million Series C financing. Proceeds from this funding round will be used to advance Decibel’s clinical and preclinical product candidates, as well as to build out the company’s comprehensive hearing drug discovery and development platform and capabilities.

The WilmerHale team representing Decibel was comprised of Lia Der Marderosian, Stephanie Singer and Jared Brenner.

Read Decibel’s press release about the financing.